NuCana’s Chemotherapy Replacement Fails to Improve Survival in Phase II Trial

Phase II Trial Failure:
NuCana's chemotherapy replacement, NUC-3373, failed to improve progression-free survival in a Phase II trial for second-line colorectal cancer patients.

Stock Price Impact:
The failure led to a 50% drop in NuCana's shares.

Previous Failures:
This is the second significant clinical failure for NuCana in two years, following the failure of acelarin (NUC-1031) in a Phase III trial for biliary tract cancer in March 2022.

Ongoing Studies:
Despite the setback, NuCana will continue to study NUC-3373 in other trials, including a Phase III study combining it with Merck's Keytruda for solid tumors and docetaxel for lung cancer.

Company Focus:
NuCana aims to improve treatment outcomes for cancer patients by transforming chemotherapy agents into more effective and safer medicines using their ProTide technology.